Compare CALY & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CALY | TLX |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | Australia |
| Employees | 28000 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | N/A | N/A |
| Metric | CALY | TLX |
|---|---|---|
| Price | $13.98 | $11.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $16.50 | ★ $21.13 |
| AVG Volume (30 Days) | ★ 2.0M | 208.0K |
| Earning Date | 05-07-2026 | 04-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.23 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $64.24 | $150.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.26 | $6.28 |
| 52 Week High | $16.65 | $19.93 |
| Indicator | CALY | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 50.44 | 78.64 |
| Support Level | $13.18 | $10.60 |
| Resistance Level | $13.96 | $12.60 |
| Average True Range (ATR) | 0.48 | 0.31 |
| MACD | 0.08 | 0.15 |
| Stochastic Oscillator | 44.83 | 90.71 |
Callaway Golf Co is a golf equipment, gear and apparel company with a portfolio of world-wide brands, including Callaway Golf, Odyssey, TravisMathew, and OGIO. Callaway designs, manufactures, and sells high-performance golf clubs, golf balls, apparel, bags, and other accessories-setting the standard for performance in the game of golf. The company has two operating and reportable business segments: Golf Equipment and Apparel, Gear and Other. Geographically, the company operates in United States, Europe, Asia, and Rest of World, of which it derives maximum revenue from United States.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.